A study of 54 calcific aortic stenosis patients versus 41 controls reveals a focused gut-heart metabolic axis driving valve calcification. Patients showed elevated inflammatory kynurenine metabolites from tryptophan breakdown, reduced protective indole-3-sulfate, and depletion of Eubacterium coprostanoligenes bacteria that normally convert cholesterol to coprostanol. Mendelian randomization suggested LDL cholesterol triggers the cascade, while tryptophan metabolites reflect downstream inflammation. This represents a significant advance in understanding how gut bacteria influence cardiovascular disease beyond the well-established TMAO pathway. The tryptophan-kynurenine axis has emerged as a key inflammatory mediator in aging and disease, but this is among the first studies linking it specifically to valvular pathology. The loss of cholesterol-metabolizing bacteria adds another layer to gut-heart interactions. For adults, this suggests gut health strategies targeting tryptophan metabolism and cholesterol-converting bacteria might complement traditional cardiac risk management. However, the modest effect sizes and limited sample size warrant caution. As a preprint awaiting peer review, these findings require validation in larger cohorts before clinical translation.